Shares of Sun Pharmaceutical
Industries today rose by nearly 3 per cent, adding Rs 3,260
crore to its market valuation, after the company received
establishment inspection report (EIR) from the US health
regulator for its Dadra facility.
The stock went up by 2.59 per cent to settle at Rs 539.40
on BSE. During the day, it advanced by 4.22 per cent to Rs
At NSE, shares of the company climbed 2.56 per cent to
close at Rs 539.55.
The company's market valuation rose by Rs 3,260.45 crore
to Rs 1,29,415.45 crore.
On the equity volume front, 5.72 lakh shares of the
company were traded on BSE and over 89 lakh shares changed
hands at NSE during the day.
The company said it had earlier indicated in the
regulatory filings to the bourses that it was in the process
of responding to the Form-483 observation letter issued by the
USFDA after the inspection of its Dadra facility.
"We are now pleased to inform you that the above referred
inspection is closed," Sun Pharma said in a BSE filing
As per the USFDA, after the completion of an inspection
of a facility, an EIR is issued to a company detailing
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)